Advertise
NEWSLETTER
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Restore, Niagen Bioscience ...
Experimental eye treatment ...
Jupiter Neurosciences doses...
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Restore, Niagen Bioscience ...
Experimental eye treatment ...
Jupiter Neurosciences doses...
inflammation

4Moving Biotech targets inflammation in knee osteoarthritis trial

Apelin agonist resulted in statistically significant improvement vs placebo in muscle size, quality, and protein synthesis in volunteers aged 65 and over.

BioAge advances inflammaging drug into Phase 2

New GlycanAge conference pushes inflammaging into care

FDA greenlights faster path for knee osteoarthritis drug

Apelin agonist resulted in statistically significant improvement vs placebo in muscle size, quality, and protein synthesis in volunteers aged 65 and over.

Inflammation’s statin moment edges closer

Mesoblast invests in smarter cell therapies with new CAR tech deal

20/20 BioLabs expands longevity test with kidney risk tech

UK nod for Soligenix drug links rare disease to healthspan

Ternary raises $4.4m to fight inflammaging with AI drugs

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed